



January 2018 Newsletter

Volume 6 Issue 1

A Letter from the Founder, Dr. Christine Brezden-Masley

Dear CCTC Members,

Happy 2018!

It has been over 6 years since the CCTC was launched in October 2011. Thank you for your continued support of the website and use of the e-referral clinical trial portal. Our next phase is to develop an 'app' so the CCTC can be more accessible at your fingertips. Watch out for this in mid-2018.

We welcome and encourage suggestions so we can continue to improve the service of the CCTC. Simply please send us an email. Our goal is to showcase as many oncology clinical trials that are open in Ontario, providing ready access for your patients.

Wishing you a very healthy and happy New Year!

Sincerely,

Dr. Christine Brezden-Masley
Founder, CCTC

A Letter from the Project Manager, Alexandra Moskalewicz

Happy New Year! I am a co-op student and BSc Candidate from the University of Waterloo, and will be the Project Manager for the CCTC until September. I have previously supported the CCTC in this role in 2016, and I am looking forward to working with the COMET community again!

If you have an accruing trial you would like to highlight, please contact me at cometrials@smh.ca to nominate it as part of our Trials of the Month.

As well, please feel free to share this newsletter with any cancer care colleagues that may be interested, as we are happy to have new members join!

Kind regards,
Alexandra Moskalewicz
Project Manager, CCTC

ARTICLE RECOMMENDATION

Searching for cures: Inner-city and rural patients' awareness and perceptions of cancer clinical trials

Geana M, Erba J, Krebill H, Doolittle G, Madhusudhana S, Qasem A, Malomo N, Sharp D
DOI: <https://doi.org/10.1016/j.conctc.2016.12.004> , Published March 2017

Objective: Fewer than 5% of cancer patients participate in clinical trials, making it challenging to test new therapies or interventions for cancer. Even within that small number, patients living in inner-city and rural areas are underrepresented in clinical trials. This study explores cancer patients' awareness and perceptions of cancer clinical trials, as well as their perceptions of patient-provider interactions related to discussing cancer clinical trials in order to improve accrual in cancer clinical trials.

Methods and Results: Interviews with 66 former and current in inner-city and rural cancer patients revealed a lack of awareness and understanding about clinical trials, as well as misconceptions about what clinical trials entail. Findings also revealed that commercials and television shows play a prominent role in forming inner-city and rural patients' attitudes and/or misconceptions about clinical trials. However, rural patients were more likely to hold unfavorable views about clinical trials than inner-city patients. Patient-provider discussions emerged as being crucial for increasing awareness of clinical trials among patients and recruiting them to trials.

Conclusion: Findings from this study will inform communication strategies to enhance recruitment to cancer clinical trials by increasing awareness and countering misconceptions about clinical trials.

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study	-	1	-	-	2	-	-	1	-	-	-	4
Observational	1	3	-	-	1	1	-	1	-	-	-	7
Prevention	-	-	-	1	-	-	-	1	-	-	-	2
Radiation	-	4	-	3	5	-	1	-	6	-	-	19
Supportive Care	1	5	-	-	-	-	-	-	-	-	-	6
Surgical Therapy	-	1	1	-	1	1	-	-	-	-	-	4
Systemic Therapy	1	9	1	14	22	6	2	9	10	7	2	83
Therapeutic	-	1	-	-	4	1	-	3	-	-	-	9
TOTAL	3	24	2	18	35	9	3	15	16	7	2	134



TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<u>PALLAS</u>	PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	<ul style="list-style-type: none"> • HER2 negative • Early breast cancer • Systemic Therapy 	Odette Cancer Centre
GU	<u>PROfound</u>	A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations	<ul style="list-style-type: none"> • Prostate Cancer • Metastatic • Therapeutic Treatment 	Odette Cancer Centre
Heme	<u>GS-US-313-1580</u>	Dose Optimization Study of Idelalisib in Follicular Lymphoma	<ul style="list-style-type: none"> • Follicular lymphoma • Refractory • Systemic Therapy 	Royal Victoria Regional Health Centre
GYN	<u>Prima</u>	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	<ul style="list-style-type: none"> • Ovarian Cancer • Advanced • Systemic Therapy 	London Health Sciences Centre
Lung	<u>B-FAST</u>	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	<ul style="list-style-type: none"> • Non-Small Cell • Metastatic • Systemic Therapy 	London Health Sciences Centre
Mel	<u>CT TEXTURE/IND.225</u>	A Phase II Study of the Assessment of Response to Pembrolizumab In Metastatic Melanoma: CT TEXTURE Analysis as a Predictive Biomarker	<ul style="list-style-type: none"> • Melanoma • Stage III/IV • Systemic Therapy 	London Health Sciences Centre Kingston General Hospital Odette Cancer Centre
GI	<u>ARTIST 1</u>	Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen	<ul style="list-style-type: none"> • Pancreatic Cancer • Metastatic • Systemic Therapy 	Odette Cancer Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



MEMBERSHIP UPDATES

275 members

31 institutions

134 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

comettrials@smh.ca

(416) 809-3915

@COMET_Trials

www.comettrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	4
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	4
Kingston General Hospital	Kingston	4	25
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	9	67
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Mount Sinai Hospital	Toronto	2	3
North York General Hospital	Toronto	14	7
Odette Cancer Centre/Sunnybrook	Toronto	55	51
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	23	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	16
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	19	11
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	15	4
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Toronto East General Hospital	Toronto	6	-
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	1	-
Wingham and District Hospital	Wingham	1	-